Comparative Pharmacology
Head-to-head clinical analysis: DROPERIDOL versus PERMITIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROPERIDOL versus PERMITIL.
DROPERIDOL vs PERMITIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Droperidol is a butyrophenone antipsychotic that acts primarily as a dopamine D2 receptor antagonist. It also exhibits antiemetic effects via blockade of dopamine D2 receptors in the chemoreceptor trigger zone. Additionally, it has alpha-adrenergic blocking properties and can prolong the QT interval by blocking cardiac potassium channels (hERG).
Antagonist at dopamine D2 receptors, also blocks alpha-1 adrenergic, histaminergic, and muscarinic receptors.
2.5-10 mg IV/IM every 3-4 hours as needed for nausea and vomiting; for agitation or psychosis in perioperative settings: 0.625-1.25 mg IV/IM, may repeat every 6 hours.
2.5-10 mg orally every 8-12 hours; maximum 40 mg/day. For severe psychosis: initial 10 mg IM, then 5-10 mg IM every 6-8 hours; maximum 30 mg/day IM.
None Documented
None Documented
Clinical Note
moderateDroperidol + Norfloxacin
"Droperidol may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateDroperidol + Ibandronate
"Droperidol may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderateDroperidol + Indapamide
"Droperidol may increase the QTc-prolonging activities of Indapamide."
Clinical Note
moderateDroperidol + Methylphenidate
"The risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate."
Terminal elimination half-life: 2.3 hours (range 1.5–4.7 hours). Clinical context: Short half-life allows rapid titration but requires repeated dosing or continuous infusion for sustained effect; accumulation with hepatic impairment.
Terminal elimination half-life: 20-30 hours; clinically, steady-state achieved in 5-7 days; prolonged in elderly and hepatic impairment
Renal (75% as metabolites, <1% unchanged); fecal (22%); biliary excretion contributes to enterohepatic circulation.
Renal: <1% unchanged; Hepatic: extensively metabolized, metabolites excreted in urine (50-60%) and feces (30-40%)
Category A/B
Category C
Antipsychotic
Antipsychotic